

Pharmx to deliver advanced vertically integrated Gateway solution, supporting Sigma's New Zealand distribution centre

Pharmx Technologies Limited (ASX: PHX) (Pharmx or the Company) is pleased to announce the first agreed work item under its multi-year Strategic Alliance with Sigma Healthcare Limited (**ASX: SIG**) (**Sigma**), following Sigma's announcement of its new distribution centre in New Zealand.

Highlights

- Pharmx will launch its vertically integrated Gateway solution to support Sigma Healthcare's new South Auckland distribution centre, the first agreed work item delivered under the multi-year Strategic Alliance announced in February 2026.
- Pharmx will now provide Gateway services between Sigma and its manufacturer partners in addition to those between Sigma and its Retail pharmacy customers, giving end to end supply chain visibility.
- The milestone reinforces Pharmx's single platform strategy and its position as core, trusted infrastructure for the ANZ pharmacy supply chain, creating a repeatable model that can be used in other selected markets, such as Australia, the UK or Ireland.
- This phase is expected to grow Pharmx's New Zealand business to approximately A\$700,000 ARR by year three of operations, representing a CAGR of ~23% over the time period, at an EBITDA margin of approximately 40%¹ in year three.
- Revenue opportunities in New Zealand, in addition to the new distribution centre, are being developed. Updates will be provided as further information can be shared.

Pharmx will support Sigma's new South Auckland distribution centre, which Sigma has confirmed will become operational from September 2026, through the launch of Pharmx's vertically integrated Gateway solution. The solution connects the supply chain from manufacturer through to store, giving a wholesaler a single, consolidated Pharmx infrastructure layer for the first time, rather than a series of disconnected point-to-point connections.

This represents a significant evolution of Pharmx's role as a network provider to the Pharmacy industry. Moving from the historical position of connecting pharmacies to wholesalers and suppliers through its Gateway, to utilising its modernised technology and data solution to create an efficient infrastructure and analytics layer through the spine of the supply chain, delivering efficiency for participants, greater

¹ Revenue is based on expected volumes to flow via a targeted supplier group using services. This includes Volumes based revenue, Store Fees and Integration fees.



reliability and greater visibility of supply chain performance supported by actionable insights to drive operational enhancements.

This services significantly expands the already strong footprint in New Zealand. Following the partnership with Toniq (announcement 18 February 2025) and subsequent rollout of services to Bargain Chemist, Pharmx now services a wide range of suppliers and stores that represent 99% of the market, whilst expanding across the vertical to support our key Strategic Alliance partner.

The initiative is strategically important for three reasons:

- Generating a new recurring revenue stream from an expanded GTV source
- Expands the Pharmx supplier network (with an estimated 100+ suppliers to join the network over the coming years)
- Creates a repeatable model that Pharmx can deploy to support Sigma and other partners across New Zealand, Australia and selected international markets as part of the Company's single platform strategy.

Pharmx expects this phase of the partnership to grow the New Zealand business to approximately \$700,000 in ARR by year three of operations, contributing to the Company's recurring revenue base and reinforcing the opportunities for growth through the Strategic Alliance.

Tom Culver, Chief Executive Officer of Pharmx, said:

"This is the first work item to be delivered under our Strategic Alliance with Sigma, and it is an important one. Supporting Sigma's New Zealand distribution centre allows us to prove our existing vertically integrated capability, high-volume environment. For the first time we are providing a Wholesaler with consolidated Pharmx infrastructure that runs from manufacturer through to store – creating a highly efficient, controllable and intelligent solution through the spine of the supply chain. That is a model we can repeat, and it is exactly the kind of accretive, strategically significant work the Strategic Alliance was designed to create. It is a strong signal of Pharmx's ability to provide core infrastructure to the pharmacy industry across our region."

The Company will continue to update the market on further work items and commercial milestones delivered under the Strategic Alliance.

ENDS

This announcement has been authorised for release by the Chairman of Pharmx Technologies Limited.

For further information, contact:

Tom Culver

Chief Executive Officer

investor.relations@pharmx.com.au



About Pharmx Technologies Limited

Pharmx is ANZ's leading pharmacy ordering platform, providing essential technology infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates approximately \$20 billion in transactions annually through its robust, high-availability platform, driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.

Forward-looking statements: This announcement contains forward-looking statements, including statements regarding expected revenue and margins. These are based on current expectations and assumptions and are subject to known and unknown risks and uncertainties. Actual results may differ materially. Pharmx does not undertake to update any forward-looking statement, except as required by law.